From the transcript:
So we have two partners who bring wealth and experience and expertise to the table in these diverse therapeutic areas and of course we benefit financially. For example, just from our alliances with Biogen Idec and AstraZeneca, we have the potential to earn more than $2.2 billion.
Last month, we also successfully completed an amendment to our collaboration with GlaxoSmithKline that provides the funding and resources to significantly accelerate the development of our TTR drug. This collaboration has been extremely successful. In just over two years we've been able to advance our TTR program from a research stage project to a drug in late stage clinical development. The amended terms of the agreement facilitate conducting a robust Phase 3 study on ISIS-TTRRx to support registration, and we plan to begin the study before the end of the year. These are just a few of our partnership successes this year.
So, to put in my own summary, Astra Zeneca focus is broad cancer market, Biogen is neurological and GSK is ISIS-TTRRx fast track designation for the treatment of familial amyloid polyneuropathy (FAP). ISIS-TTRRx is an antisense drug in development with GlaxoSmithKline (GSK) for the treatment of transthyretin (TTR) amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. Isis and GSK recently amended the clinical development plan and financial terms relating to ISIS-TTRRx to support a registration-directed Phase 2/3 clinical study on ISIS-TTRRx, which is expected to start this month.